Advances in Therapy

, Volume 30, Issue 2, pp 127–151 | Cite as

The Impact of 7-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease: A Literature Review

  • Tin Tin Htar Myint
  • Harish Madhava
  • Paul Balmer
  • Dina Christopoulou
  • Sepideh Attal
  • Damianos Menegas
  • Ralf Sprenger
  • Eric Bonnet
Open Access
Review

Abstract

Introduction

Streptococcus pneumoniae can cause invasive pneumococcal diseases (IPD), such as bacteremic pneumonia, bacteremia, meningitis, and sepsis, and non-IPDs, such as otitis media, nonbacteremic pneumonia, and upper respiratory tract infections. It was estimated in 2000 that, worldwide, S. pneumoniae was responsible for 826,000 deaths annually in children aged between 1 month and 5 years. A 7-valent pneumococcal conjugate vaccine (PCV7) was licensed in 2000 in the USA and in 2001 in Europe.

Methods

A literature search was performed in PubMed to identify studies assessing the impact of routine childhood PCV7 vaccination on pneumococcal morbidity and mortality. Here, the impact on IPD is reported.

Results

A total of 37 articles reporting impact data on IPD were included in this review: four from Australia, 17 from western Europe, and 16 from North America. In vaccine-eligible children in the postvaccination period, a reduction ranging from 39.9% in Spain to 99.1% in the USA in vaccine-type (VT) IPD incidence, compared with the prevaccination period, was reported in 18 studies. All but one of the 30 studies assessing the impact of PCV7 on all-type IPD reported a reduction ranging from 1.7% in Spain to 76.3% in Australia. In addition, the majority of studies reported reductions in VT and all-type IPD incidence in age groups that were not vaccine eligible.

Conclusions

The results from this review illustrate that PCV7 has had a significant impact on IPD across all ages through its use in pediatric immunization programs. With the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) further reductions in the incidence of IPD due to the six additional serotypes included, as well as continued protection against IPD due to PCV7 serotypes may be expected. Robust surveillance systems are essential for the evaluation of the impact of PCV13 on all-type IPD and for monitoring the evolution of non-VT IPD.

Keywords

Direct vaccine impact Immunology Indirect vaccine impact Infectious diseases Invasive pneumococcal disease Streptococcus pneumoniae Vaccine impact 7-valent pneumococcal conjugate vaccine 

References

  1. 1.
    Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348.PubMedCrossRefGoogle Scholar
  2. 2.
    Frenck RW Jr, Yeh S. The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. Expert Opin Biol Ther. 2012;12:63–77.PubMedCrossRefGoogle Scholar
  3. 3.
    O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902.PubMedCrossRefGoogle Scholar
  4. 4.
    Pebody RG, Hellenbrand W, D’Ancona F, Ruutu P. Pneumococcal disease surveillance in Europe. Euro Surveill. 2006;11:171–8.PubMedGoogle Scholar
  5. 5.
    Rosen JB, Thomas AR, Lexau CA, et al. CDC Emerging Infectious Program Network. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis. 2011;53:137–143.Google Scholar
  6. 6.
    Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31:501–508.PubMedCrossRefGoogle Scholar
  7. 7.
    Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines. 2009;8:1351–1364.PubMedCrossRefGoogle Scholar
  8. 8.
    Zangeneh TT, Baracco G, Al-Tawfiq JA. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections. Expert Rev Vaccines. 2011;10:345–353.PubMedCrossRefGoogle Scholar
  9. 9.
    World Health Organization. Pneumococcal conjugate vaccine for childhood immunization — WHO position paper. Wkly Epidemiol Rec. 2007;82:93–104.Google Scholar
  10. 10.
    Rendi-Wagner P, Paulke-Korinek M, Kundi M, et al. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases. Vaccine. 2009;27:3963–3968.PubMedCrossRefGoogle Scholar
  11. 11.
    Hanquet G, Lernout T, Vergison A, et al. Belgian IPD Scientific Committee. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine. 2011;29:2856–2864.PubMedCrossRefGoogle Scholar
  12. 12.
    Harboe ZB, Valentiner-Branth P, Benfield TL, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine. 2010;28:2642–2647.PubMedCrossRefGoogle Scholar
  13. 13.
    Rückinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27:4136–4141.PubMedCrossRefGoogle Scholar
  14. 14.
    Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010;16:816–823.PubMedCrossRefGoogle Scholar
  15. 15.
    Vestrheim DF, Lovoll O, Aaberge IS, et al. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008;26:3277–3281.PubMedCrossRefGoogle Scholar
  16. 16.
    Vestrheim DF, Hoiby EA, Bergsaker MR, Ronning K, Aaberge IS, Caugant DA. Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine. 2010;28:2214–2221.PubMedCrossRefGoogle Scholar
  17. 17.
    Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin Infect Dis. 2009;48:57–64.PubMedCrossRefGoogle Scholar
  18. 18.
    Aristegui J, Bernaola E, Pocheville I, et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2007;26:303–310.PubMedCrossRefGoogle Scholar
  19. 19.
    Barricarte A, Gil-Setas A, Torroba L, et al. Invasive pneumococcal disease in children younger than 5 years in Navarra, Spain (2000–2005). Impact of the conjugate vaccine [in Spanish]. Med Clin (Barc). 2007;129:41–45.CrossRefGoogle Scholar
  20. 20.
    Calbo E, Diaz A, Canadell E, et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect. 2006;12:867–872.PubMedCrossRefGoogle Scholar
  21. 21.
    Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47:1012–1020.PubMedCrossRefGoogle Scholar
  22. 22.
    Guevara M, Barricarte A, Gil-Setas A, et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect. 2009;15:1013–1019.PubMedCrossRefGoogle Scholar
  23. 23.
    Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174–182.PubMedCrossRefGoogle Scholar
  24. 24.
    Perez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, Perez-Yarza EG. Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2009;28:731–738.PubMedCrossRefGoogle Scholar
  25. 25.
    Foster D, Walker AS, Paul J, et al. Oxford Invasive Penumococcal Surveillance Group. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol. 2011;60:91–97.Google Scholar
  26. 26.
    Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760–768.PubMedCrossRefGoogle Scholar
  27. 27.
    Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1569–1576.PubMedCrossRefGoogle Scholar
  28. 28.
    Black S, France EK, Isaacman D, et al. Surveillance for invasive pneumococcal disease during 2000–2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26:771–777.PubMedCrossRefGoogle Scholar
  29. 29.
    Whitney CG, Farley MM, Hadler J, et al. Active Bacterial Core Surveillance of the Emerging Infectious Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737–1746.PubMedCrossRefGoogle Scholar
  30. 30.
    Lexau CA, Lynfield R, Danila R, et al. Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043–2051.PubMedCrossRefGoogle Scholar
  31. 31.
    Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196:1346–1354.PubMedCrossRefGoogle Scholar
  32. 32.
    Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction — eight states, 1998–2005. MMWR Morb Mortal Wkly Rep. 2008;57:144–148.Google Scholar
  33. 33.
    Pilishvili T, Lexau C, Farley MM, et al. Active Bacterial Core Surveillance/Emerging Infectious Program. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Hennessy TW, Singleton RJ, Bulkow LR, et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine. 2005;23:5464–5473.PubMedCrossRefGoogle Scholar
  35. 35.
    Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784–1792.PubMedCrossRefGoogle Scholar
  36. 36.
    Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J. Massachusetts Department of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J. 2005;24:17–23.PubMedCrossRefGoogle Scholar
  37. 37.
    McBean AM, Park YT, Caldwell D, Yu X. Declining invasive pneumococcal disease in the US elderly. Vaccine. 2005;23:5641–5645.PubMedCrossRefGoogle Scholar
  38. 38.
    Pulido M, Sorvillo F. Declining invasive pneumococcal disease mortality in the United States, 1990–2005. Vaccine. 2010;28:889–892.PubMedCrossRefGoogle Scholar
  39. 39.
    Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio. 2011;2:e00309–00310.PubMedCrossRefGoogle Scholar
  40. 40.
    Tsigrelis C, Tleyjeh IM, Lahr BD, Nyre LM, Virk A, Baddour LM. Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995–2007: a population-based study. Clin Infect Dis. 2008;47:1367–1371.PubMedCrossRefGoogle Scholar
  41. 41.
    Tyrrell GJ, Lovgren M, Chui N, et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000–2006. Vaccine. 2009;27:3553–3560.PubMedCrossRefGoogle Scholar
  42. 42.
    Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae Research (CASPER) study. Clin Infect Dis. 2009;49:205–212.PubMedCrossRefGoogle Scholar
  43. 43.
    Hanna JN, Humphreys JL, Murphy DM, Smith HV. Invasive pneumococcal disease in non-indigenous people in north Queensland, 2001–2009. Med J Aust. 2010;193:392–396.PubMedGoogle Scholar
  44. 44.
    Lehmann D, Willis J, Moore HC, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis. 2010;50:1477–1486.PubMedCrossRefGoogle Scholar
  45. 45.
    Roche PW, Krause V, Cook H, et al. Pneumococcal Working Party of the Communicable Disease Network Australia. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell. 2008;32:18–30.Google Scholar
  46. 46.
    Williams SR, Mernagh PJ, Lee MH, Tan JT. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust. 2011;194:116–120.PubMedGoogle Scholar
  47. 47.
    Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage among children aged 19–35 months — United States, 2004. MMWR Morb Mortal Wkly Rep. 2005;54:717–721.Google Scholar
  48. 48.
    Broder KR, MacNeil A, Malone S, et al. Who’s calling the shots? Pediatricians’ adherence to the 2001–2003 pneumococcal conjugate vaccine-shortage recommendations. Pediatrics. 2005;115:1479–1487.PubMedCrossRefGoogle Scholar
  49. 49.
    HM Government. data.gov.uk. NHS Information Centre for Health and Social Care. NHS Immunisation Statistics England 2009-10. London: 2010. Available at: http://data.gov.uk/dataset/nhs-immunisation-statistics-england-2009-10. Accessed Jan 21 2013.
  50. 50.
    Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact of pneumococcal conjugate vaccine on the epidemiology of invasive pneumococcal diseases in France - 1998-2010 [in French]. 2010 [cited Jun 14 2012]. Available at: http://www.invs.sante.fr/surveillance/epibac/donnees_2010/pneumocoque_impact_2010.pdf. Accessed Jun 14 2012.Google Scholar
  51. 51.
    Office federal de la sante publique et Commission federale pour les vaccinations. Pneumococcal vaccination recommendations for children under five years old. Replacement of 7-valent conjugate vaccine by 13-valent conjugate vaccine [in French]. 2010 [cited Nov 9 2012]; Available from: http://www.bag.admin.ch/themen/medizin/00682/00684/01097/index.html?lang=fr#sprungmarke1_2. Accessed Nov 9 2012.
  52. 52.
    Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017–1026.PubMedCrossRefGoogle Scholar
  53. 53.
    Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29:9127–9131.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2013

Authors and Affiliations

  • Tin Tin Htar Myint
    • 1
  • Harish Madhava
    • 2
  • Paul Balmer
    • 2
  • Dina Christopoulou
    • 2
  • Sepideh Attal
    • 3
  • Damianos Menegas
    • 4
  • Ralf Sprenger
    • 5
  • Eric Bonnet
    • 1
  1. 1.Pfizer ESAT VaccinesParisFrance
  2. 2.Pfizer Ltd., Pfizer Europe, Walton OaksTadworthUK
  3. 3.Pfizer FranceParisFrance
  4. 4.Pfizer Hellas AEN. Psychico AthensGreece
  5. 5.Pfizer GermanyBerlinGermany

Personalised recommendations